MedTrace Logo

A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children

NCT02965404 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2017-10-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of a live attenuated varicella vaccine in healthy adults, adolescents, and children.

Conditions

  • Varicella

Interventions

BIOLOGICAL

Investigational live attenuated varicella vaccine

The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

BIOLOGICAL

control live attenuated varicella vaccine

The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)

BIOLOGICAL

diluent of lyophilized vaccine

The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology

Sponsors & Collaborators

  • Sinovac (Dalian) Vaccine Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Shengli Xia · Henan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-05-31
Completion
2016-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965404 on ClinicalTrials.gov